BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCTX) Stock Overview
Explore BriaCell Therapeutics Corp.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
14M
P/E Ratio
-0.38
EPS (TTM)
$-7.69
ROE
-4.40%
BCTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of BriaCell Therapeutics Corp. (BCTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 22.51, suggesting the stock is in an oversold condition. Our forecasting models predict significant price movements, with a 12-month target of $0.58.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.38 and a market capitalization of 14M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
William V. Williams FCPA,
16
Bellevue Centre, West Vancouver, BC
2012